Catabasis Pharmaceuticals, Inc. ( CATB) Stock. Should you Buy or Sell? $ 8.54
-0.64 (-8.10 %)
Catabasis Pharmaceuticals, Inc. Analysis
Updated on 10-09-2022| Symbol | CATB |
| Price | $8.54 |
| Beta | 1.663 |
| Volume Avg. | $528.92 thousand |
| Market Cap | $657.14 M |
| 52 Week Range | $1.25 - $10.26 |
Catabasis Pharmaceuticals, Inc. opened the day at $8.54 which is -8.10 % on yesterday's close. Catabasis Pharmaceuticals, Inc. has a 52 week high of $10.26 and 52 week low of $1.25, which is a difference of $9.01. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $657.14 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Catabasis Pharmaceuticals, Inc. for $657.14 M, it would take 15 years to get your money back. Catabasis Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Catabasis Pharmaceuticals, Inc. Stock Forecast - Is Catabasis Pharmaceuticals, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Neutral | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | 0.000 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Catabasis Pharmaceuticals, Inc.
| Price Book Value Ratio | 0.000 | Price To Book Ratio | 0.000 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | 0.000 |
How liquid is Catabasis Pharmaceuticals, Inc.
| Current Ratio | 0.000 |
| Quick Ratio | 0.000 |
Debt
| Debt Ratio | 0.000 | Debt Equity Ratio | 0.000 |
| Long Term Debt To Capitalization | 0.000 | Total Debt To Capitalization | 0.000 |
Latest news about Catabasis Pharmaceuticals, Inc.
Once-struggling, Catabasis Pharmaceuticals Inc (NASDAQ: CATB) is looking to hit the reset button with a new name and focus. Catabasis has been dragging for several years, weighed down mainly by the failure of the edasalonexent program in Duchenne muscular dystrophy.
Catabasis Pharmaceuticals Inc (NASDAQ: CATB) deployed a reverse stock split of its shares of common stock at a ratio of 1-for-6. These are the details.
Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
The stock price of Catabasis Pharmaceuticals Inc (NASDAQ: CATB) increased by over 40% pre-market. This is why it happened.
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
About Catabasis Pharmaceuticals, Inc.
Description :
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.
